1. Home
  2. TRVI vs RA Comparison

TRVI vs RA Comparison

Compare TRVI & RA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRVI
  • RA
  • Stock Information
  • Founded
  • TRVI 2011
  • RA 2016
  • Country
  • TRVI United States
  • RA United States
  • Employees
  • TRVI N/A
  • RA 1260
  • Industry
  • TRVI Biotechnology: Pharmaceutical Preparations
  • RA Investment Managers
  • Sector
  • TRVI Health Care
  • RA Finance
  • Exchange
  • TRVI Nasdaq
  • RA Nasdaq
  • Market Cap
  • TRVI 629.8M
  • RA 715.0M
  • IPO Year
  • TRVI 2019
  • RA N/A
  • Fundamental
  • Price
  • TRVI $5.76
  • RA $12.93
  • Analyst Decision
  • TRVI Strong Buy
  • RA
  • Analyst Count
  • TRVI 8
  • RA 0
  • Target Price
  • TRVI $19.31
  • RA N/A
  • AVG Volume (30 Days)
  • TRVI 1.0M
  • RA 280.8K
  • Earning Date
  • TRVI 05-08-2025
  • RA 01-01-0001
  • Dividend Yield
  • TRVI N/A
  • RA 14.73%
  • EPS Growth
  • TRVI N/A
  • RA N/A
  • EPS
  • TRVI N/A
  • RA N/A
  • Revenue
  • TRVI N/A
  • RA N/A
  • Revenue This Year
  • TRVI N/A
  • RA N/A
  • Revenue Next Year
  • TRVI N/A
  • RA N/A
  • P/E Ratio
  • TRVI N/A
  • RA N/A
  • Revenue Growth
  • TRVI N/A
  • RA N/A
  • 52 Week Low
  • TRVI $2.30
  • RA $11.89
  • 52 Week High
  • TRVI $7.39
  • RA $17.32
  • Technical
  • Relative Strength Index (RSI)
  • TRVI 56.14
  • RA 48.68
  • Support Level
  • TRVI $6.08
  • RA $12.80
  • Resistance Level
  • TRVI $6.47
  • RA $12.95
  • Average True Range (ATR)
  • TRVI 0.39
  • RA 0.07
  • MACD
  • TRVI -0.00
  • RA 0.00
  • Stochastic Oscillator
  • TRVI 45.06
  • RA 50.00

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

About RA Brookfield Real Assets Income Fund Inc.

Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities. The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.

Share on Social Networks: